Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Sopheon Funding Award

19 Oct 2017 07:00

RNS Number : 9906T
Sopheon PLC
19 October 2017
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Awarded Funding for European Research Projects

 

Funding recognizes Sopheon's ongoing contribution to research on market disrupters such as Internet of Things, real-time decision support, and advanced analytics embedded into business process

 

Sopheon, the international provider of software, expertise, and best practices for Enterprise Innovation Performance, today announced the award of European funding for innovative research in the framework of the EUREKA/ITEA research program alongside a consortium of project partners. The funding is for two different projects, Medolution (https://itea3.org/project/medolution.html) and PARTNER (https://itea3.org/project/partner.html).

 

Both research projects focus on developing innovative and intelligent methods and software for real time handling of massive volumes of data across complex scenarios, with emphasis on the healthcare industry. Sopheon's contribution to these projects focuses on applying the data-driven decision support capabilities of our Accolade® software. Sopheon benefits in return from the collaboration with project partners − research institutes and leading software companies such as Philips Healthcare, Atos/Bull, Siemens Healthcare, Barco, IMEC, KPN and NXP Semiconductors - to develop breakthrough capabilities for commercial application in our software.

 

In the current digital age, organizations are looking for technologies that allow them to handle unprecedented amounts of information, with speed. This information is drawn from a very incoherent landscape of IT systems and sources, within as well as beyond the physical boundaries of the enterprise. The data to be handled comes from many different sources - structured and unstructured data; metadata from sensor data, images, video - and is reused in the context of big data analysis, internet of things (IoT) techniques, cloud services, etc.

 

The Accolade software is able to interpret all of this data in real time, irrespective of source or format, based on rules and criteria defined by domain experts and within predefined best practice protocols that are managed by the Accolade system.

 

Huub Rutten, VP Research and Application Development at Sopheon, stated: "For Sopheon the research is very applicable to our core enterprise innovation management clients and future product strategy. Our work in these projects positions us to develop relationships with some of the leading companies in the world for commercial leverage, and to develop innovative strategic technologies and applications for our target markets. Further, our research discoveries also have the potential to open new market segments for our application."

 

This award brings to a total of five the number of research grants awarded to Sopheon since 2009.

 

Sopheon® and Accolade® are trademarks of Sopheon 

 

 

For further information contact:

Barry Mence, ChairmanArif Karimjee, CFO

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes / Giles Rolls (corporate finance)

Mia Gardener (corporate broking)

finnCap Ltd

+ 44 (0) 20 7220 0500

 

 

About Eureka. EUREKA (http://www.eurekanetwork.org/) is an intergovernmental organization for pan-European research and development funding and coordination. EUREKA aims to coordinate efforts of governments, research institutes and commercial companies concerning innovation.

 

About ITEA. ITEA (https://itea3.org/) is the EUREKA Cluster program supporting innovative, industry-driven, pre-competitive R&D projects in the area of Software-intensive Systems & Services (SiSS). ITEA stimulates projects in an open community of large industry, SMEs, universities, research institutes, and user organizations.

 

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete Enterprise Innovation Management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAOKFDNQBDDQKD
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.